A recent study published in Cardiovascular Diabetology assessed the efficacy and safety of canagliflozin in patients with T2DM based on cardiovascular CV disease history or CV risk factors. These post hoc analyses were based on pooled data from four 26 week placebo controlled Phase 3 studies that evaluated canagliflozin 100 and 300 mg in patients with T2DM. The findings showed that at week 26 both canagliflozin doses lowered glycosylated hemoglobin HbA1c body weight and systolic BP compared to placebo in patients with and without CV disease history or risk factors. Placebo subtracted HbA1c reductions with canagliflozin 100 and 300 mg were comparable in patients with a history of CV disease and in those with no history of CV disease history of hypertension when compared to those with no history of hypertension baseline statin use when compared to those with no statin use and 0 1 CV risk factor when compared to those with 8805 2 CV risk factors. Whereas body weight and systolic BP reductions were equivalent with canagliflozin and placebo across subgroups. Furthermore the incidence of adverse events AEs AEs leading to discontinuation and serious AEs were similar across subgroups. Hence it was inferred that the efficacy and safety of canagliflozin is generally consistent across subgroups of patients with T2DM and varying degrees of CV disease history or risk factors.